• Soligenix Announces SGX301Study Continues to Demonstrate Positive Benefits americanpharmaceuticalreview
    October 29, 2020
    Soligenix announced continued optional treatment with SGX301 (synthetic hypericin) across all lesions during the compassionate use, safety portion of the trial (Cycle 3), for a total of 6 months in the study, continued to significantly improve responses..
PharmaSources Customer Service